Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Quality of life in patients with advanced prostate cancer after apalutamide treatment

Posted by on Jan 12, 2020 in Prostate cancer | 0 comments

In a nutshell This study analyzed the health-related quality of life (HRQOL) in patients with metastatic castration-sensitive prostate cancer (MCSPC) after treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT). The study found that apalutamide plus ADT was well tolerated and improved survival compared to ADT alone in these...

Read More

The role of androgen deprivation therapy plus radiotherapy in the treatment of prostate cancer after prostate surgery

Posted by on Jan 12, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of short-term androgen deprivation therapy (ADT) combined with radiotherapy (RT) in patients who underwent radical prostatectomy (RP). The main finding was that the combination of ADT and RT reduced the risk of recurrence and disease progression in these patients. Some background RP is...

Read More

Abiraterone acetate and prednisone in patients with metastatic, castration‑sensitive prostate cancer

Posted by on Dec 30, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment...

Read More

Searching for patients to try a radiation treatment strategy for prostate cancer.

Posted by on Dec 20, 2019 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of ultra-high-dose hypofractionated or single-dose radiotherapy for intermediate (medium) risk prostate cancer. The main outcome that will be measured will be the number of patients that experience side effects. This study is being conducted in New York City, NY, the US. The details...

Read More

My Oncologist Doesn’t Believe Food Is Necessary

My Oncologist Doesn’t Believe Food Is Necessary

Posted by on Dec 3, 2019 in Blog, Breast cancer, Colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 1 comment

By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...

Read More

What are the effects of radical prostatectomy without pelvic lymph node dissection in prostate cancer?

Posted by on Nov 29, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated the outcomes of radical prostatectomy (RP) without pelvic lymph node dissection (PLND) in patients with prostate cancer. The main finding was that 5 years after treatment, 100% of patients at low risk for cancer recurrence had survived. Some background PLND is surgery to remove the lymph nodes from the pelvis....

Read More

What are the effects of salvage stereotactic radiotherapy (SSRT) in prostate cancer relapse after prostate surgery?

Posted by on Nov 28, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated the effects of salvage stereotactic radiotherapy (SSRT) in patients with prostate bed recurrence after prostate surgery. The main finding was that SSRT was effective at curing or delaying prostate cancer recurrence. Some background Almost 30% of men who undergo radical prostatectomy (complete removal of the...

Read More

Evaluating the outcomes of cabazitaxel treatment for patients with prostate cancer

Posted by on Nov 26, 2019 in Prostate cancer | 0 comments

In a nutshell This study examined the effectiveness of cabazitaxel (Jevtana) in patients with prostate cancer that has spread. This study concluded that cabazitaxel improved patient outcomes more than conventional hormone therapy. Some background Androgen deprivation therapy (ADT) remains a standard treatment for patients with prostate cancer....

Read More

Evaluating docetaxel plus hormone therapy for the treatment of metastatic prostate cancer

Posted by on Nov 3, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of docetaxel (Taxotere) plus hormone therapy for patients with metastatic prostate cancer (cancer that spread outside the prostate). This study found that this treatment combination improved survival for these patients, regardless of tumor burden. Some background One treatment for...

Read More

Evaluating different radiotherapy doses for patients with prostate cancer

Posted by on Oct 28, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated whether fewer sessions of radiotherapy at a higher dose was more effective than conventional radiotherapy for patients with prostate cancer. The authors found that fewer radiation sessions at a higher dose did not increase side effects. Some background Radiation therapy is an effective treatment for prostate...

Read More

Evaluating the overall survival in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Posted by on Oct 27, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated the effect of apalutamide (Erleada) on survival in patients with castrate-resistant prostate cancer (CRPC). This study found that apalutamide had a positive effect on the survival of these patients. Some background One treatment option for patients with prostate cancer is androgen deprivation therapy...

Read More